Company
Headquarters: Lomianki, Poland
Employees: 518
CEO: Dr. Maciej Wieczorek Ph.D.
€181.5 Million
EUR as of Jan. 1, 2024
US$200.5 Million
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Celon Pharma S.A., an integrated pharmaceutical company, researches, manufactures, and markets drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. The company was founded in 2002 and is based in Lomianki, Poland. Celon Pharma S.A. is a subsidiary of Glatton Sp. z o.o.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Celon Pharma SA has the following listings and related stock indices.
Stock: FSX: 8RP wb_incandescent